86
Participants
Start Date
September 12, 2023
Primary Completion Date
June 12, 2025
Study Completion Date
March 31, 2026
PRT2527
PRT2527 will be administered by intravenous infusion once weekly.
Zanubrutinib
Zanubrutinib will be provided in capsules for oral administration once or twice daily.
Venetoclax
Venetoclax will be provided in tablet for oral administration once daily
Alfred Health, Melbourne
Austin Health, Heidelberg
Monash Health, Melbourne
Linear Clinical Research Ltd, Perth
Ente Ospedaliero Cantonale (EOC) lstituto Oncologico della Svizzera italiana (IOSl)- Ospedale San Giovanni (ORBV), Bellinzona
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
American Oncology Partners of Maryland, PA, Bethesda
University of Virginia Comprehensive Cancer Center, Charlottesville
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola, Bologna
Keimyung_University Dongsan Hospital, Daegu
"lstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST", Meldola
lnje University Busan Paik Hospital, Busan
Ospedale Santa Maria delle Croci - AUSL della Romagna, Ravenna
Universitatsklinikum Koln, Klinik I fur lnnere Medizin, Cologne
Claude Huriez Hospital, Lille
City of Hope, Duarte
Institut Curie, Saint-Cloud
Hopital Henri Mondor, Créteil
Dana-Farber Cancer Institute, Boston
Jewish General Hospital, Montreal
Centre Léon Bérard, Lyon
Pratia MCM Krakow, Krakow
Samsung Medical Center, Seoul
The Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds
Lead Sponsor
Collaborators (1)
BeiGene
INDUSTRY
Prelude Therapeutics
INDUSTRY